Document Detail

Five-Year Outcomes in Patients With Chronic Total Coronary Occlusion Treated With Drug-Eluting vs Bare-Metal Stents: A Case-Control Study.
MedLine Citation:
PMID:  23265094     Owner:  NLM     Status:  Publisher    
BACKGROUND: Limited data exist on long-term safety and effectiveness of drug-eluting stents (DESs) in true chronic total coronary occlusion (CTO) settings. We evaluated 5-year clinical outcomes of patients with CTO treated successfully with DES vs bare-metal stent (BMS). METHODS: We compared the 5-year clinical outcomes of 156 patients treated with DES implantation with outcomes of a historical cohort of 159 patients treated with BMS. Primary end point was freedom from major adverse cardiac events (MACEs; defined as death, myocardial infarction [MI], and target lesion revascularization [TLR]); secondary end points were freedom from target vessel failure (TVF; combination of target vessel revascularization, MI, and cardiac death) and TLR at 5 years. RESULTS: After 5 years, the DES group had significantly superior event-free survival from MACE (84% vs 69%; log rank P < 0.001), TVF (71% vs 84%; P = 0.002), and TLR (77% vs 92%; P = 0.0001), compared with the BMS group. The Cox proportional hazards model identified BMS vs DES (adjusted hazard ratio [HR] = 3.37; 95% confidence interval [CI], 1.85-6.17; P = 0.001), final minimal lumen diameter (HR, 0.27; 95% CI, 0.14-0.52; P = 0.0001), and stent length (HR, 1.01; 95% CI, 1.00-1.03; P = 0.03) as independent predictors of MACE at 5-year follow-up. Twelve (7%) and 7 (4%) stent thromboses occurred in the DES and BMS groups (P = 0.23), respectively. CONCLUSIONS: After 5 years, DESs were superior to BMSs in reducing MACE, TVF, and TLR in patients with CTO and should be the preferred strategy.
Francesco De Felice; Rosario Fiorilli; Antonio Parma; Carmine Musto; Marco Stefano Nazzaro; Massimiliano Scappaticci; Pierpaolo Confessore; Elena Guerra; Flavia Belloni; Roberto Violini
Related Documents :
19700194 - Primary end point (six months) results of the ranibizumab for edema of the macula in di...
19996834 - Visual outcome after intravitreal ranibizumab for wet age-related macular degeneration:...
20417564 - Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangiom...
23444494 - Argatroban: for a few selected patients.
6394004 - Cefaclor versus ampicillin for outpatient treatment of urinary tract infections.
9127134 - Evaluation of gestrinone after surgery in treatment of endometriosis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-19
Journal Detail:
Title:  The Canadian journal of cardiology     Volume:  -     ISSN:  1916-7075     ISO Abbreviation:  Can J Cardiol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8510280     Medline TA:  Can J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
UO Cardiologia Interventistica Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Advances in Cardiac SPECT and PET Imaging: Overcoming the Challenges to Reduce Radiation Exposure an...
Next Document:  Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: IMPACT-CABG pilot ...